Evidence map›Paper›PMID 32865201›Full record

ReviewThe Journal of clinical endocrinology and metabolism2020

Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.

Anand Vaidya, Robert M Carey

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05262660 unknown statusnot on this mapstarted 2022, after this paper: background citation

The Long-term Effect of Superselective Adrenal Arterial Embolization and Medical Treatment for Primary Aldosteronism on Cardiorenovascular Protection, Blood Pressure, and the Endocrinological Profile.

Typeobservational_patient_registrySponsorFirst Affiliated Hospital of Chengdu Medical CollegeRan2022 to 2025Enrolled400ConditionsPrimary Aldosteronism
NCT06740838 recruitingnot on this mapstarted 2024, after this paper: background citation

Overnight Dexamethasone in Primary Aldosteronism Screening in Patients on Interfering Therapy (the ODEPRASC Study)

TypeobservationalSponsorMedical University of GdanskRan2024 to 2026Enrolled240ConditionsPrimary Aldosteronism, Hypertension
3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 135 citations in OpenAlex.

  1. Gender Differences in Cardiac Organ Damage in Arterial Hypertension: Assessing the Role of Drug Nonadherence.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Hypertensive Disorders of Pregnancy and Primary Aldosteronism.Hypertension (Dallas, Tex. : 1979) · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Hypertensive Disorders of Pregnancy and Primary Aldosteronism.medRxiv : the preprint server for health sciences · 2026
    Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Anand VaidyaCenter for Adrenal Disorders, Division of Endocrinology, Diabetes, & Hypertension, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Robert M CareyDivision of Endocrinology and Metabolism, University of Virginia Health System, Charlottesville, Virginia.
Brigham and Women's Hospital · USUniversity of Virginia Health System · US

Funding

Spatiotemporal transregulation of D1-like angiotensin receptors in genetically...P01HL074940 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GILDEA, JOHN JOSEPH · 2004 to 2020
$31.8M
Unrecognized Primary Aldosteronism as a Pathogenic Mechanism for Chronic Kidney Disease in DiabetesR01DK115392 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Anand Vaidya · 2018 to 2026
$6.0M
Adrenal Origins of Aldosterone ExcessR01DK106618 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI William E Rainey, Aaron Mark Udager · 2016 to 2026
$6.0M
Renal AT2 Receptors in HypertensionR01HL128189 · NHLBI · UNIVERSITY OF VIRGINIA · PI KELLER, SUSANNA R · 2016 to 2024
$5.0M
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in ObesityR01HL153004 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, ANAND · 2020 to 2024
$4.4M
NHLBI NIH HHS P01 HL074940NHLBI NIH HHS R01 HL128189NHLBI NIH HHS R01 HL153004NIDDK NIH HHS R01 DK106618NIDDK NIH HHS R01 DK115392
6 · The paper itself

Abstract

contextNew approaches are needed to address the evolution of the primary aldosteronism syndrome and to increase its recognition. Herein, we review evidence indicating that primary aldosteronism is a prevalent syndrome that is mostly unrecognized, and present a pragmatic and pathophysiology-based approach to improve diagnosis and treatment.

methodsEvidence was gathered from published guidelines and studies identified from PubMed by searching for primary aldosteronism, aldosterone, renin, and hypertension. This evidence was supplemented by the authors' personal knowledge, research experience, and clinical encounters in primary aldosteronism. INTERPRETATION OF EVIDENCE: Renin-independent aldosterone production is a prevalent phenotype that is diagnosed as primary aldosteronism when severe in magnitude, but is largely unrecognized when milder in severity. Renin-independent aldosterone production can be detected in normotensive and hypertensive individuals, and the magnitude of this biochemical phenotype parallels the magnitude of blood pressure elevation, the risk for incident hypertension and cardiovascular disease, and the likelihood and magnitude of blood pressure reduction with mineralocorticoid receptor antagonist therapy. Expansion of the indications to screen for primary aldosteronism, combined with the use of a pathophysiology-based approach that emphasizes inappropriate aldosterone production in the context of renin suppression, will substantially increase the diagnostic and therapeutic yields for primary aldosteronism.

conclusionsThe landscape of primary aldosteronism has evolved to recognize that it is a prevalent syndrome of renin-independent aldosterone production that contributes to the pathogenesis of hypertension and cardiovascular disease. Expanding screening indications and simplifying the diagnostic approach will enable implementation of targeted treatment for primary aldosteronism.

Indexed as

AldosteroneBlood PressureDiagnostic Techniques, EndocrineHumansHyperaldosteronismHypertensionMass ScreeningPractice Guidelines as TopicPrevalencePrognosisReninSyndromeAldosteroneReninadrenalaldosteronehypertensionprimary aldosteronismrenin

Identifiers

PMID32865201
PMCPMC7899564
OpenAlexW3082493155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.